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PERSPECTIVE OPEN
Towards tailored and targeted adherence assessment
to optimise asthma management
Job FM van Boven1, Jaap CA Trappenburg2, Thys van der Molen3 and Niels H Chavannes4
In this paper, we aim to emphasise the need for a more comprehensive and tailored approach to manage the broad nature of non-
adherence, to personalise current asthma management. Although currently several methods are available to measure the extent of
asthma patients’ adherence, the vast majority do not incorporate conﬁrmation of the actual inhalation, dose and inhalation
technique. Moreover, most current measures lack detailed information on the individual consequences of non-adherence and on
when and how to take action if non-adherence is identiﬁed. Notably, one has to realise there are several forms of non-adherence
(erratic non-adherence, intelligent non-adherence and unwitting non-adherence), each requiring a different approach. To improve
asthma management, more accurate methods are needed that integrate measures of non-adherence, asthma disease control and
patient preferences. Integrating information from the latest inhaler devices and patient-reported outcomes using mobile
monitoring- and feedback systems (‘mHealth’) is considered a promising strategy, but requires careful implementation. Key issues
to be considered before large-scale implementation include patient preferences, large heterogeneity in patient and disease
characteristics, economic consequences, and long-term persistence with new digital technologies.
npj Primary Care Respiratory Medicine (2015) 25, 15046; doi:10.1038/npjpcrm.2015.46; published online 16 July 2015
INTRODUCTION
A key driver for asthma treatment success is the extent to which
patients adhere to their prescribed pharmacological regimen.1
Good adherence encompasses multiple dimensions, including
intensity and timing of use according to prescription (compliance),
continuous use (persistence) and correct use (inhalation
technique).2,3 Non-adherence to asthma medication is associated
with poor clinical, humanistic and economic outcomes.4–6 Previous
studies showed that adherence to asthma medications on average
is far from optimal. Depending on methods, population and
setting, estimates of non-adherence typically range between 30
and 75% in both adults and children.7,8 Current methods to
measure medication adherence include direct biochemical mea-
surement, clinician judgment, self-report, assessment of prescrip-
tion reﬁll data and the use of electronic devices.8,9 These methods
all have their advantages and disadvantages. However, an
important limitation that most methods share is that they do not
incorporate conﬁrmation of actual inhalation, dose and inhalation
technique. Furthermore, most methods fail to provide detailed
information on the individual consequences of non-adherence and
on when and how to take action if non-adherence is identiﬁed.
Therefore, more accurate methods are required that integrate
measures of the broad nature of non-adherence and essential
elements of asthma control. Combining patient-reported outcomes
with the latest inhalation-, adherence monitoring- and feedback
systems offers a promising new strategy.
The aim of this paper is to assess the value of current asthma
adherence measures in relation to the management of diverse types
of non-adherence, levels of asthma control and patient preferences
and engagement. Subsequently, a more comprehensive non-
adherence-managing approach is proposed and discussed.
IDENTIFICATION OF PAPERS
To identify relevant papers, a semi-structured search in Pubmed
and Cochrane was performed with several combinations of the
following search terms: adherence, asthma, inhalers, mobile
phone and electronic monitoring. Papers deemed relevant were
studied, and additional papers were retrieved through searching
the references.
THE BROAD NATURE OF ASTHMA NON-ADHERENCE
In the management of asthma, good understanding of the
diversity and complexity of patient adherence is required.2 As
such, the World Health Organization has deﬁned three types of
non-adherence: erratic non-adherence, intelligent non-adherence
and unwitting non-adherence.2
Currently, the terms intentional and unintentional non-
adherence are also commonly used.10
Erratic non-adherence
Erratic non-adherence is probably the most well-known type of
non-adherence. This form of unintentional non-adherence is often
referred to as forgetfulness.2 Patients have the intention to be as
adherent as possible, but simply cannot combine the medication
regimen with their busy daily life.
Intelligent non-adherence
A patient with ‘intelligent’, or intentional, non-adherence, purposely
alters, discontinues, or even fails to initiate prescribed therapy.
This deliberate non-adherence reﬂects a reasoned choice, albeit
not necessarily a wise one.2 Patients who ‘feel’ better may decide
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that they no longer need to take their medications, i.e., their illness
perception has an important role.11 A number of factors may be
responsible: fear of perceived short- or long-term side effects; taste;
complexity; interference with daily life; cost; disagreement with
provider regarding need. All these factors may cause patients to
choose to avoid daily therapy.2,11
Unwitting non-adherence
Another form of unintentional non-adherence is unwitting non-
adherence. Unwitting non-adherence is the failure to understand
fully either the speciﬁcs of the regimen or the necessity for
adherence.2 Unwitting non-adherent patients make no intentional
decision to be non-adherent. Studies have repeatedly conﬁrmed
that patients frequently forget instructions given to them during a
clinic visit.12 In asthma management, it is common for patients to
misunderstand the difference between ‘as needed’ medication
and maintenance medication. Another example of common
‘unwitting non-adherence’ is poor inhaler technique.3,13,14
MANAGING NON-ADHERENCE IN ASTHMA: NOT SIMPLY
ONE-SIZE FITS-ALL
Most of the erratic non-adherent patients could be helped by
straightforward interventions such as simpliﬁcation of the dosing
regimen, electronic reminders, or the advice to link the intake of
medication to a daily habit.2 In contrast, patients that are
intelligent non-adherent do not need any reminders, but may
be more likely to beneﬁt from a process of shared decision making
and motivational interviewing.15 Finally, unwitting non-adherent
patients are expected to beneﬁt from extra education.9 For this
purpose, self-management and written action plans have been
widely recommended in international and many national
guidelines.16,17 The effectiveness of these plans has been
proven;18 however, uptake of written action plans is still
suboptimal.19,20 In addition, there is room for improvement of
the speciﬁc elements impacting effectiveness of these plans,
especially regarding suitability in patients with limited literacy.21
Patients with poor inhalation technique would be helped by more
information and training to enhance their skills regarding inhaler
use. Thereby it should be mentioned that training and education
on inhalation technique have to be provided by well-trained
healthcare professionals. Notably, some studies suggest that there
is ample room for improvement regarding medical personnel’s
knowledge on inhalation devices.22,23
DETECTING SPECIFIC TYPES OF NON-ADHERENCE IN ASTHMA:
CURRENT LIMITATIONS
To aid the healthcare provider in detecting and assessing asthma
patients’ adherence, several methods are available. Most com-
monly used methods include direct biochemical measurement
(e.g., in blood or other body ﬂuids), judgment of healthcare
providers, patient self-report, assessment of prescription reﬁll data,
and the use of electronic monitoring devices.8,9 In general, the
speciﬁc value of the current measurement methods regarding
detecting and managing erratic non-adherence, intelligent non-
adherence and unwitting non-adherence has been under-
reported, but is considered a key issue for optimal management
and outcomes. For example, erratic non-adherence often remains
unnoticed until exacerbations occur.5 Intelligent non-adherence
may be detected during patient interviews with a healthcare
provider, given that the patient is willing to share his concerns.10
However, the topic is often only covered substantially in the
consultation room once it is too late (e.g., after severe exacerba-
tions). Another possibility to detect intelligent non-adherence is
by the use of validated self-report instruments such as the MARS-A
questionnaire.24 Yet, asking the patient might result in a ‘socially
acceptable answer’ and thereby an overestimation of actual
adherence.25,26 Unwitting non-adherence, e.g., a poor inhalation
technique, might be diagnosed by a healthcare provider
observing the patient, but usually there would need to be another
reason for consultation ﬁrst. Although guidelines highlight the
importance of regular inhalation technique assessment as part of
every asthma review, real-life practice often falls short.17,27
Currently, patients themselves cannot rely on valid instruments
to assess the quality of their inhalation.
The value of current methods regarding the three types of
non-adherence and other aspects is compared and summarised
in Table 1. For a more extensive comparison, we refer to previous
reviews that compared adherence measurement methods in
asthma.8,9,28 Table 1 was the result of thorough assessment of
these previous reviews and a ﬁnal consensus between the authors
of this article.
Direct biochemical measurement is an unbiased method to
assess actual intake, but is costly and invasive and only provides a
point estimate of adherence.9,28 In-depth patient interviews by a
healthcare provider can provide insight in most types of non-
adherent behaviour, yet they require regular face-to-face meet-
ings and effective patient–provider communication to obtain a
continuous measure.10,29 Longitudinal measurement of adherence
by prescription reﬁlls provides a continuous and remotely
accessible alternative.28 However, this method of measuring
adherence lacks discriminative properties regarding the three
types of non-adherence and cannot detect a poor inhalation
technique.
In general, most methods routinely used fail to take into
account the interaction between different forms of non-adherence
and variations in asthma control, thereby wasting the opportu-
nities for tailored, proactive interventions. In conclusion, each of
the current methods available has its strengths, but none of the
methods are optimal for tailored asthma non-adherence
management.
OPTIMISING ADHERENCE ASSESSMENT IN ASTHMA:
REQUIREMENTS
Without disregarding the value of a good initial diagnosis and the
wide availability of a basic level of asthma care, the limitations
described in the previous section demonstrate the need for an
integrated, personal, approach to deal with the broad nature of
asthma non-adherence. This approach needs to take into account
not only the type of non-adherence, but also patient preferences
and asthma control (Figure 1). In our view, this requires the digital
integration of the latest inhalation technology and asthma control
monitoring tools in a patient-preference-based environment.
Detection of non-adherence
Ideally, non-adherence detection aids will provide us with both a
qualitative measure of adherence (e.g., inhaler handling and
inhalation technique) and a continuous, quantitative measure to
detect all types of non-adherence. The quantitative measure
includes the frequency, hour of the day and time interval between
inhalations. Electronic monitoring devices, attached or integrated
in inhalation devices, appear the most promising to capture both
aspects.30 These electronic devices have been recommended as
the reference standard to assess medication adherence in both
research and real-world clinical settings.31 Technically, these
devices have shown their feasibility and some have been available
on the healthcare market for almost 20 years, although they are
still primarily used in small-scale research settings.32 Examples of
monitoring devices that are able to log the date and time of
actuations are the SmartMist, Doser CT, MDIlog and the Nebulizer
Chronolog, of which studies demonstrated that all devices were
sufﬁciently accurate.33,34 A more recent development is the
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Propeller Health sensor that not only keeps a record of time and
date, but also of location of use.35 Another development is the
Smartinhaler that automatically sends usage data to a mobile
application or computer via Bluetooth and can provide discreet
audio-visual reminders if the patient forgets to take the prescribed
medication.36 Yet, all devices still do not assess the quality of
inhalation. A promising new technique relies on the use of
acoustic inhalation measurements. In research settings, time-
stamped acoustic recordings seem to be a suitable method for
monitoring inhalation technique over time.32,37 Interestingly, an
association between better adherence and changes in asthma
quality of life and peak expiratory ﬂow was only found when
adherence was operationalised as both time of use and inhalation
technique, and not for time of use only.32 These developments
illustrate that some of the technology to introduce an electronic
monitoring component within asthma management is already
available.
Asthma control
Two of the most frequently used health status tools to measure
asthma control are the Asthma Control Questionnaire (ACQ-6) and
the Asthma Control Test.38,39 In current clinical practice, these
tools are only occasionally used, most often during regular patient
consultations. Interventions following from these asthma control
scores are generally reactive. In contrast, continuous digital
monitoring of asthma control would enable early detection of
increasing symptoms and proactive interventions. Theoretically,
whenever ACQ/Asthma Control Test scores exceed a certain
threshold (based on previous scores and preferences), alerts and
decision support could be sent to the patient and/or healthcare
provider. Subsequently, initial remote assessment of the patient
(e-consultations) could be performed, only followed by active in-
person consultation if deemed relevant. In stable periods, no
consultations would be needed, even when non-adherence is
signalled. First results from studies assessing e-consultations
showed that patients were satisﬁed with an e-consultation
process,40 but research is still very limited and no speciﬁc studies
in asthma have been performed. Therefore, more studies are
obviously necessary before large-scale implementation should
take place.
Patient preferences
The asthma population is very heterogeneous regarding its needs,
preferences and capabilities.41 For example, patients with low
health literacy and self-management ability may need a different
approach, especially as these aspects are associated with
worsened outcomes.42,43 Also patients’ current use and
Table 1. Characteristics of current asthma medication adherence measurement tools
Green: positive; orange: medium; red: negative.
Figure 1. Personalised asthma adherence management by taking
into account three domains.
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preferences towards mobile phone-based management may have
a role in both uptake and effectiveness of this digital strategy. In
renal transplant recipients, 79% showed a positive attitude
towards mobile phone-based adherence and health monitoring,
but their attitude was positively inﬂuenced by smartphone
ownership.44 In asthma, disease severity and comorbidities may
inﬂuence patients’ preferences and abilities for more or less self-
care.45 A cross-sectional study indicated that about 60% of the
asthma patients preferred an active or collaborative role in
treatment decisions and 40% a passive role, regardless of disease
severity.46 As regards this heterogeneity, a three-point approach
to enhance patients’ motivation and to optimise outcomes has
been suggested.47 This approach includes counselling on the
necessity of asthma medication, addressing patients’ concerns
about medication, and tailoring the choice of the treatment
regimen to patients’ preferences and capacities.
In addition, the possibility for asthma patients to interact with
their peer patients may be beneﬁcial. Peer-to-peer contact has
been shown to improve self-efﬁcacy and asthma control with
favourable cost-effectiveness; however, studies are limited.48–50
Finally, acceptance of digital asthma health care, in particular,
depends on age, duration of disease, education and use of
computers/Internet.51
THE CONCEPT OF INTEGRATING ADHERENCE MEASUREMENT,
ASTHMA CONTROL AND PATIENT PREFERENCES
Developments in inhalation technology and digital asthma control
measurement are promising. These technologies offer the
potential to enhance adherence and tailor asthma management,
that could result in improved quality of life and reduced
healthcare utilisation.3,4,52,53 However, to achieve optimal inter-
vention uptake and effect size, careful conceptualisation of the
design is essential. Ideally, adherence measurements of electronic
inhalation devices are directly transferred to an mHealth platform
on a mobile phone. First, this will provide patients with real-time
insight in their own medication-taking behaviour, but second,
these data can be extracted during regular consultations with
their healthcare providers. It is unlikely that the healthcare
provider will be monitoring these signals on a daily basis, but
the server could be set up to issue alarms, should control fall
outside of certain preset levels. The information gathered would
help in the performance of the next structured asthma review. In
this context, such a system could fall under M for Monitoring in
SIMPLES or under S for Support.54 Integrating information
regarding the timing and quality of inhalations with patient-
reported outcomes has the potential to provide the full picture;
that is, it may be able to signal patterns regarding forms of non-
adherence and subsequent poor asthma control. On the basis of
these observations, personalised treatment and recommendations
can be provided, depending on patients’ needs. For some
patients, automatically generated, but tailored, feedback by
decision-aid systems may be sufﬁcient. For other patients,
however, direct in-person and digital consultations are required
for optimal patient-centred care, education and outcomes. In
addition, the digital platform will allow patients to interact with
their peers. It may also serve as a place where healthcare providers
can provide general treatment and lifestyle recommendations,
given that patient conﬁdentiality is always taken into account.
A global outline of this approach is visualised in Figure 2. It
includes the use of a smartinhaler combined with a mobile
phone application to measure adherence and asthma control,
tailored decision support and motivational feedback, and
optional digital or direct face-to-face contacts with healthcare
providers and/or peer patients. As depicted, several opportunities
for tailored asthma management are offered, depending on
patients’ and healthcare providers’ needs and preferences (more
self-management or more guidance by healthcare providers) and
feasibility studies.
OPTIMISING ADHERENCE ASSESSMENT IN ASTHMA:
CONSIDERATIONS
This integrated approach seems promising and ﬁts well with the
current movement towards personalised, predictive, preventive
and participatory respiratory medicine (‘P4 medicine’).55 Yet, an
important barrier to innovation is that technologies such as these
are often considered to be too costly.56 Regarding the innovative
technology itself, it is expected that product costs will rapidly
decrease over time.30 Less predictable, however, are the economic
consequences of this potential shift from primarily ‘scheduled’
chronic care to future ‘on-demand’ care. It is likely that face-to-
face consultations would reduce as the patients learnt better how
to control their disease.57 It is, however, unclear whether this
would also lead to fewer hospitalisations. Therefore, careful
analysis of current chronic digital asthma care is necessary. A
review by Huckvale et al.58 systematically assessed the content of
103 asthma apps and compared the contents to international
guidelines and best practices. The authors concluded that none of
the different apps combined reliable information about asthma
with supportive tools for self-management. A recent Cochrane
review reported on the effectiveness and cost-effectiveness of
digital apps for asthma self-management and found that the
current evidence is not sufﬁcient to advise large-scale
implementation.59
Long-term adherence to these technologies is one of the other
issues that should be taken into account. A study from 2004
suggested that patients used an asthma-monitoring website only
for a limited amount of time.60 Note that this study was performed
in times before the smartphone era. A more recent study, by van
Gaalen et al.,61 did indeed show persistence of effect in the
intervention group. Evidence of the economic dimension of more
comprehensive digital asthma management tools suggest neutral
to unfavourable cost-effectiveness, but evidence is limited and
highly dependent on implementation and current technology
costs.57,62
The question rises whether this technology should be restricted
to selected populations. Should we for instance focus on the mild
asthma population, in whom fewer in-person contacts may be
safe, or should we focus on the persistent asthma population,
where disease burden and costs are highest? Another possibility is
Figure 2. Integrated asthma adherence management approach.
Solid red lines: standard mHealth decision support; dashed red lines:
optional pathway, depending on patient and healthcare provider
preferences and feasibility studies.
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that these technologies become an integrated part of the
medication, just as is currently the case with existing inhaler
devices. Manufacturers would not only provide the pharmacolo-
gical component, but also the technology to assist patients and
healthcare providers in optimising asthma disease management.
Especially in the current era of limited major pharmacological
breakthroughs but a wealth of new inhalers available, the
provision of these kinds of services may signiﬁcantly increase
the added value of manufacturers and make them stand out from
the rest. Other issues that need to be addressed include privacy
issues, data ownership, and digital competences of patients and
healthcare providers.
In general, the most successful telemonitoring implementations
have occurred when all of the basics (including sample size,
intervention, duration of follow-up and deﬁnition of outcomes)
have been done properly and monitoring is integrated into a
system that is ready to receive it.63 However, these systems are
much less likely to have a positive impact unless all the other
prerequisites are in place, which is why so many telemonitoring
trials fail to demonstrate beneﬁt. When used as part of an
integrated pathway,64 mHealth support has the opportunity to
improve asthma outcomes, but more research regarding optimal
implementation is highly required.
CONCLUSION
Current measures to assess asthma non-adherence do not provide
sufﬁcient information. More targeted and personalised methods,
combining measures of non-adherence, asthma control and patient
preferences are needed. Mobile monitoring systems offer a
promising integrated approach to assess (non)-adherence and
optimise asthma management, but require careful implementation.
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